Oncolytics Biotech (NASDAQ:ONCY) Director Deborah Margaret Brown Buys 25,000 Shares

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Deborah Margaret Brown purchased 25,000 shares of the stock in a transaction dated Thursday, February 12th. The shares were acquired at an average cost of $0.85 per share, for a total transaction of $21,250.00. Following the completion of the acquisition, the director directly owned 109,851 shares of the company’s stock, valued at approximately $93,373.35. This trade represents a 29.46% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Oncolytics Biotech Stock Up 27.0%

Shares of NASDAQ ONCY opened at $1.06 on Friday. Oncolytics Biotech Inc. has a fifty-two week low of $0.33 and a fifty-two week high of $1.51. The stock has a market cap of $112.52 million, a P/E ratio of -3.79 and a beta of 0.99. The firm’s 50-day simple moving average is $0.98 and its 200 day simple moving average is $1.07.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. On average, sell-side analysts anticipate that Oncolytics Biotech Inc. will post -0.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oncolytics Biotech

Hedge funds have recently modified their holdings of the stock. Scientech Research LLC purchased a new stake in shares of Oncolytics Biotech during the 3rd quarter worth about $25,000. Security National Bank of Sioux City Iowa IA bought a new stake in Oncolytics Biotech in the fourth quarter worth approximately $29,000. Seeds Investor LLC increased its stake in shares of Oncolytics Biotech by 17.8% during the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock worth $173,000 after purchasing an additional 33,826 shares during the last quarter. Ground Swell Capital LLC bought a new position in shares of Oncolytics Biotech during the 4th quarter valued at $30,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of Oncolytics Biotech in the 4th quarter valued at $44,000. 6.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Zacks Research upgraded shares of Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. HC Wainwright boosted their price target on shares of Oncolytics Biotech from $5.00 to $10.00 and gave the company a “buy” rating in a report on Monday, November 17th. Wall Street Zen lowered shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.25.

Key Oncolytics Biotech News

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.